Delirium at the End of Life
- PMID: 32312411
- DOI: 10.1016/j.mcna.2020.01.006
Delirium at the End of Life
Abstract
Delirium is a prevalent acute neurocognitive condition in patients with progressive life-limiting illness. Delirium remains underdetected; a systematic approach to screening is essential. Delirium at the end of life requires a comprehensive assessment. Consider the potential for reversibility, illness trajectory, patient preference, and goals of care before proceeding with investigations and interventions. Management should be interdisciplinary, and nonpharmacologic therapy is fundamental. For patients with refractory and severe agitation or perceptual disturbance, judicious use of medication may also be required. Carers and family should be seen as partners in care and be involved in shared decision making about care.
Keywords: Antipsychotics; Benzodiazepines; Delirium; Delirium pathophysiology; Delirium prevention; Delirium screening; End of life; Palliative care.
Copyright © 2020 Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosure M. Agar has received funding from the National Health and Medical Council, National Breast Cancer Foundation and Cancer Australia for Delirium Clinical Trials. S.H. Bush has received research funding from the Bruyère Academic Medical Organization, National Breast Cancer Foundation and Cancer Australia for Delirium Clinical Trials. M. Agar and S.H. Bush did not receive any funding for this article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical